Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Caccese

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Frontiers in Oncology|January 1, 2024
Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated <i>MGMT</i> gene promoter: RACTAC, a phase II multicenter trialAndrea Pace, Giuseppe Lombardi, Veronica Villani, et al.
Cancer Treatment Reviews|November 12, 2024
PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectivesEugenia Cella, Alberto Bosio, Pasquale Persico, et al.
Trials|August 4, 2025
Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study)Alberto Bosio, Giulia Cerretti, Marta Padovan, et al.
Journal of Neuro-Oncology|June 1, 2023
Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter studyMario Caccese, Isacco Desideri, Marta Padovan, et al.
Frontiers in Oncology|December 11, 2023
Spinal ependymoma in adults: from molecular advances to new treatment perspectivesGiulia Cerretti, Federico Pessina, Enrico Franceschi, et al.
Patient Preference and Adherence|February 17, 2022
Cancer Patient-Reported Experience Measures (PREMs) Regarding the Policies Implemented to Contain the Spread of Sars-CoV-2 and Vaccination Campaign at Veneto Institute of OncologyMario Caccese, Silvia Imbevaro, Alessandra Feltrin, et al.
Journal of Neuro-Oncology|March 10, 2025
Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experienceGiulia Cerretti, Alberto Bosio, Giovanni Librizzi, et al.
Neuro-Oncology Practice|May 11, 2026
Real-world management and long-term outcomes in adolescent, young adult, and adult medulloblastoma: Experience from a monocentric series with multimodal and targeted approachesAlberto Bosio, Marta Maccari, Marta Padovan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2020
Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker AnalysisStefano Indraccolo, Gian Luca De Salvo, Martina Verza, et al.
Cancers|May 28, 2022
Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter StudyMario Caccese, Matteo Simonelli, Veronica Villani, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Frontiers in Oncology|January 1, 2024
Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated <i>MGMT</i> gene promoter: RACTAC, a phase II multicenter trialAndrea Pace, Giuseppe Lombardi, Veronica Villani, et al.
Cancer Treatment Reviews|November 12, 2024
PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectivesEugenia Cella, Alberto Bosio, Pasquale Persico, et al.
Trials|August 4, 2025
Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study)Alberto Bosio, Giulia Cerretti, Marta Padovan, et al.
Journal of Neuro-Oncology|June 1, 2023
Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter studyMario Caccese, Isacco Desideri, Marta Padovan, et al.
Frontiers in Oncology|December 11, 2023
Spinal ependymoma in adults: from molecular advances to new treatment perspectivesGiulia Cerretti, Federico Pessina, Enrico Franceschi, et al.
Patient Preference and Adherence|February 17, 2022
Cancer Patient-Reported Experience Measures (PREMs) Regarding the Policies Implemented to Contain the Spread of Sars-CoV-2 and Vaccination Campaign at Veneto Institute of OncologyMario Caccese, Silvia Imbevaro, Alessandra Feltrin, et al.
Journal of Neuro-Oncology|March 10, 2025
Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experienceGiulia Cerretti, Alberto Bosio, Giovanni Librizzi, et al.
Neuro-Oncology Practice|May 11, 2026
Real-world management and long-term outcomes in adolescent, young adult, and adult medulloblastoma: Experience from a monocentric series with multimodal and targeted approachesAlberto Bosio, Marta Maccari, Marta Padovan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2020
Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker AnalysisStefano Indraccolo, Gian Luca De Salvo, Martina Verza, et al.
Cancers|May 28, 2022
Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter StudyMario Caccese, Matteo Simonelli, Veronica Villani, et al.
Pageof 6